当前位置:首页 - 行情中心 - 立方制药(003020) - 财务分析 - 利润表

立方制药

(003020)

  

流通市值:24.43亿  总市值:34.13亿
流通股本:1.14亿   总股本:1.60亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入1,524,501,6531,267,790,879.76811,816,8182,579,340,227.28
营业收入1,524,501,6531,267,790,879.76811,816,8182,579,340,227.28
二、营业总成本1,357,619,917.081,134,992,117.8730,374,001.922,376,803,278.74
营业成本815,399,383.49721,723,165.67515,196,866.061,615,062,657.34
税金及附加12,800,392.599,983,592.175,661,811.7815,958,116.03
销售费用426,697,055.82331,810,137.82183,366,298.26616,385,532.44
管理费用46,562,333.1731,073,547.1715,164,043.1359,140,037.93
研发费用59,933,416.4542,799,903.6912,539,427.673,803,566.1
财务费用-3,772,664.44-2,398,228.72-1,554,444.91-3,546,631.1
其中:利息费用532,670.691,245,078.23111,613.92890,229.81
其中:利息收入4,386,501.133,696,303.551,557,113.874,391,502.57
加:公允价值变动收益2,388,524.441,380,091.84-3,860.64-38,177.44
加:投资收益27,502,965.8319,793,055.44-365,672.6332,291,486.22
资产处置收益--3,823.43-1,358.92-2,543,813.15
资产减值损失(新)-5,499,770.47-3,155,525.52-2,412,527.26-3,781,506.29
信用减值损失(新)-3,851,895.1-5,764,914.98-1,578,521.58-239,152.21
其他收益3,909,811.881,972,543.64843,372.0611,829,136.22
营业利润平衡项目0000
四、营业利润191,331,372.5147,020,188.9577,924,247.11240,054,921.89
加:营业外收入254,037.33190,688.06111,158.88424,203.16
减:营业外支出678,004.79561,612.73948.74655,808.72
利润总额平衡项目0000
五、利润总额190,907,405.04146,649,264.2878,034,457.25239,823,316.33
减:所得税费用18,076,720.3615,520,014.1811,892,777.2330,215,749.49
六、净利润172,830,684.68131,129,250.166,141,680.02209,607,566.84
持续经营净利润172,830,684.68131,129,250.166,141,680.02209,607,566.84
归属于母公司股东的净利润171,375,218.46131,129,250.166,141,680.02209,607,566.84
少数股东损益1,455,466.22---
(一)基本每股收益1.090.820.541.74
(二)稀释每股收益1.090.820.541.74
九、综合收益总额172,830,684.68131,129,250.166,141,680.02209,607,566.84
归属于母公司股东的综合收益总额171,375,218.46131,129,250.166,141,680.02209,607,566.84
归属于少数股东的综合收益总额1,455,466.22---
公告日期2023-10-312023-08-292023-04-182023-04-18
审计意见(境内)标准无保留意见
TOP↑